Agronomics Limited, the Investment company focused on alternative proteins and food technology, announced on 13 November 2026 that its portfolio company Solar Foods had received a positive scientific opinion from the European Food Safety Authority for its Solein ingredient. The news came two days after a wider portfolio update in which the company highlighted several holdings that it believes are approaching potential Revenue catalysts.
What the company does
Agronomics invests in early and growth-stage companies developing new ways of producing food and materials, with a focus on cellular agriculture and precision fermentation. These technologies aim to produce proteins, fats and other ingredients without relying on conventional livestock farming. The company's portfolio includes businesses such as Formo, Solar Foods, Clean Food Group, Meatly, Galy and SuperMeat. Its value is reported through a regularly published net asset value, which stood at £139.5 million at 30 September 2026.
Latest developments
According to the 13 November announcement, the positive EFSA opinion moves Solar Foods' novel food application for Solein into the final authorisation stage, though it is not final approval. Around seven to nine months are estimated to remain before authorisation, after which the product could be sold across the European Union. The opinion is also expected to support offtake negotiations and financing for Solar Foods' planned second factory. Agronomics has invested £5.2 million in Solar Foods, and the holding was carried at about £6.4 million, or around 4.6% of net asset value.
The portfolio update on 11 November highlighted that Formo had received a US Food and Drug Administration "no questions" letter for an enhanced casein ingredient used in cheese alternatives. Formo was Agronomics' largest featured holding, carried at £9.4 million against £3.8 million invested. Clean Food Group has commercialised an oil product for skincare, Galy plans a US launch of a consumer product in December 2026, and Meatly, which completed a £10.4 million Series A round in May, aims to begin production in 2027. In May, Agronomics also led a US$5 million investment in SuperMeat.
Financial and Dividend picture
As an investment company, Agronomics generates returns mainly through changes in the value of its holdings rather than through trading revenue. It publishes its net asset value quarterly, and the most recent figure of £139.5 million relates to 30 September 2026. No dividend information was found in the announcements reviewed, and investors typically look to growth in net asset value and eventual exits from portfolio companies.
Sector and index context
Agronomics is one of the more specialised investment vehicles in the FTSE AIM All Share Index. The alternative protein sector attracted heavy investment in earlier years, but funding conditions have since become more demanding, and many companies have had to show progress on regulatory approvals and commercial production. Approvals in the European Union, the United States and elsewhere are important milestones because they open markets to products that would otherwise be unable to be sold.
Key risks
Most portfolio companies are early stage and loss-making, so their valuations depend on future funding rounds and commercial success that may not materialise. Regulatory processes can be slow, and approvals are not guaranteed. Scaling up production is technically demanding and Capital intensive. Valuations of unlisted holdings involve judgement and can change significantly, and the company's share price may differ from its reported net asset value.
What to watch next
Investors will follow Solar Foods' progress towards final EU authorisation, Galy's planned US launch, Meatly's production plans and further funding rounds across the portfolio. The next net asset value update, covering the quarter to 31 December 2026, will also be closely watched.
_11_16_2026_12_39_02_969239.jpg)





Please wait processing your request...